Sessa C, Viganò L, Grasselli G, Trigo J, Marimon I, Lladò A, Locatelli A, Ielmini N, Marsoni S, Gianni L

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

Eur J Cancer 2006; 171-8. doi: 10.1016/j.ejca.2005.09.033

Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

Ann Oncol 2007; 561-8. doi: 10.1093/annonc/mdl418

Sessa C, Perotti A, Lladò A, Cresta S, Capri G, Voi M, Marsoni S, Corradino I, Gianni L

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

Ann Oncol 2007; 1548-53. doi: 10.1093/annonc/mdm198

Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

Eur J Cancer 2009; 2116-22. doi: 10.1016/j.ejca.2009.04.002

Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, Pisano C, Carminati P, D'Incalci M

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

Eur J Cancer 2010; 505-16. doi: 10.1016/j.ejca.2009.11.006

Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Clin Cancer Res 2010; 2474-82. doi: 10.1158/1078-0432.CCR-09-3042

Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G

Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.

Breast Cancer Res Treat 2010; 399-411. doi: 10.1007/s10549-010-0887-y

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

J Clin Oncol 2010; 3219-26. doi: 10.1200/JCO.2009.27.1825

Floriani I, Garassino MC, Broggini M, Veronese S, Marsoni S, Marabese M, Farina G, Scanni A

Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?

J Clin Oncol 2010; e467; author reply e468. doi: 10.1200/JCO.2010.28.5973

Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

J Clin Oncol 2010; 4554-61. doi: 10.1200/JCO.2009.27.5867

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

J Natl Cancer Inst 2011; 863-75. doi: 10.1093/jnci/djr153

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

J Clin Oncol 2012; 996-1004. doi: 10.1200/JCO.2010.34.5074

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Int J Gynecol Cancer 2012; 792-800. doi: 10.1097/IGC.0b013e318251051a

Mandalà M, Grosso F, Vitalini C, Corradino I, Sanfilippo R, Colombini S, Clerici M, Labianca R, De Pascale A, Marsoni S

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.

Br J Cancer 2012; 612-6. doi: 10.1038/bjc.2012.325

Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.

Br J Cancer 2012; 1025-30. doi: 10.1038/bjc.2012.371

Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.

Eur J Cancer 2013; 290-6. doi: 10.1016/j.ejca.2012.09.009

de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, D'Antonio C, Dal Zotto L, Al-Batran SE, Marsoni S, Wolf M

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.

J Thorac Oncol 2013; 1091-4. doi: 10.1097/JTO.0b013e318293d88c

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Lancet Oncol 2013; 981-8. doi: 10.1016/S1470-2045(13)70310-3

Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Ann Oncol 2014; 1222-8. doi: 10.1093/annonc/mdu108

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Clin Cancer Res 2014; 5663-71. doi: 10.1158/1078-0432.CCR-14-0719

Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Ann Oncol 2015; 2079-84. doi: 10.1093/annonc/mdv318

Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.

Oncotarget 2015; 34014-22. doi: 10.18632/oncotarget.5607

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA, Trusolino L, Velculescu VE

The genomic landscape of response to EGFR blockade in colorectal cancer.

Nature 2015; 263-7. doi: 10.1038/nature14969

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Mod Pathol 2015; 1481-91. doi: 10.1038/modpathol.2015.98

Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, Sapino A, Sottile A, Sarotto I, Casorzo L, Cassoni P, De Simone M, Comoglio PM, Marsoni S, Corso S, Giordano S

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

Oncogene 2017; 1200-1210. doi: 10.1038/onc.2016.283

Corso S, Isella C, Bellomo SE, Apicella M, Durando S, Migliore C, Ughetto S, D'Errico L, Menegon S, Moya-Rull D, Cargnelutti M, Capelôa T, Conticelli D, Giordano J, Venesio T, Balsamo A, Marchiò C, Degiuli M, Reddavid R, Fumagalli U, De Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Pietrantonio F, Morano F, Siena S, Sartore-Bianchi A, Bencivenga M, Mengardo V, Rosati R, Marrelli D, Morgagni P, Rausei S, Pallabazzer G, De Simone M, Ribero D, Marsoni S, Sottile A, Medico E, Cassoni P, Sapino A, Pectasides E, Thorner AR, Nag A, Drinan SD, Wollison BM, Bass AJ, Giordano S

A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits.

Cancer Res 2019; 5884-5896. doi: 10.1158/0008-5472.CAN-19-1166

Wagner AD, Grothey A, Andre T, Dixon JG, Wolmark N, Haller DG, Allegra CJ, de Gramont A, VanCutsem E, Alberts SR, George TJ, O'Connell MJ, Twelves C, Taieb J, Saltz LB, Blanke CD, Francini E, Kerr R, Yothers G, Seitz JF, Marsoni S, Goldberg RM, Shi Q

Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.

J Natl Cancer Inst 2021; 400-407. doi: 10.1093/jnci/djaa124

Giannini V, Rosati S, Defeudis A, Balestra G, Vassallo L, Cappello G, Mazzetti S, De Mattia C, Rizzetto F, Torresin A, Sartore-Bianchi A, Siena S, Vanzulli A, Leone F, Zagonel V, Marsoni S, Regge D

Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.

Int J Cancer 2020; 3215-3223. doi: 10.1002/ijc.33271

Rizzetto F, Calderoni F, De Mattia C, Defeudis A, Giannini V, Mazzetti S, Vassallo L, Ghezzi S, Sartore-Bianchi A, Marsoni S, Siena S, Regge D, Torresin A, Vanzulli A

Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases.

Eur Radiol Exp 2020; 62. doi: 10.1186/s41747-020-00189-8

Corso S, Pietrantonio F, Apicella M, Migliore C, Conticelli D, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Ughetto S, Degiuli M, Reddavid R, Fumagalli U, De Pascale S, Sgroi G, Rausa E, Baiocchi GL, Molfino S, De Manzoni G, Bencivenga M, Siena S, Sartore-Bianchi A, Morano F, Corallo S, Prisciandaro M, Di Bartolomeo M, Gloghini A, Marsoni S, Sottile A, Sapino A, Marchiò C, Dahle-Smith A, Miedzybrodzka Z, Lee J, Ali SM, Ross JS, Alexander BM, Miller VA, Petty R, Schrock AB, Giordano S

Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas.

Clin Cancer Res 2021; 3126-3140. doi: 10.1158/1078-0432.CCR-20-0121

Ughetto S, Migliore C, Pietrantonio F, Apicella M, Petrelli A, D'Errico L, Durando S, Moya-Rull D, Bellomo SE, Rizzolio S, Capelôa T, Ribisi S, Degiuli M, Reddavid R, Rapa I, Fumagalli U, De Pascale S, Ribero D, Baronchelli C, Sgroi G, Rausa E, Baiocchi GL, Molfino S, Manenti S, Bencivenga M, Sacco M, Castelli C, Siena S, Sartore-Bianchi A, Tosi F, Morano F, Raimondi A, Prisciandaro M, Gloghini A, Marsoni S, Sottile A, Sarotto I, Sapino A, Marchiò C, Cassoni P, Guarrera S, Corso S, Giordano S

Personalized therapeutic strategies in HER2-driven gastric cancer.

Gastric Cancer 2021; 897-912. doi: 10.1007/s10120-021-01165-w

Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice MG, Luise C, Erreni M, Pece S, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.

Cancer Cell 2021; 708-724.e11. doi: 10.1016/j.ccell.2021.03.004

Jin Z, Dixon JG, Fiskum JM, Parekh HD, Sinicrope FA, Yothers G, Allegra CJ, Wolmark N, Haller D, Schmoll HJ, de Gramont A, Kerr R, Taieb J, Van Cutsem E, Tweleves C, O'Connell M, Saltz LB, Sadahiro S, Blanke CD, Tomita N, Seitz JF, Erlichman C, Yoshino T, Yamanaka T, Marsoni S, Andre T, Mahipal A, Goldberg RM, George TJ, Shi Q

Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

J Natl Cancer Inst 2021; 1693-1704. doi: 10.1093/jnci/djab123

Macagno M, Pessei V, Congiusta N, Lazzari L, Bellomo SE, Idrees F, Cavaliere A, Pietrantonio F, Raimondi A, Gusmaroli E, Zampino MG, Gervaso L, Ciardiello D, Mondello G, Santoro A, Personeni N, Bonoldi E, Aquilano MC, Valtorta E, Siena S, Sartore-Bianchi A, Amatu A, Bonazzina EF, Bencardino KB, Serini G, Marsoni S, Barault L, Di Nicolantonio F, Maione F

A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection.

Diagnostics (Basel) 2024; . doi: 10.3390/diagnostics14222467

Amatu A, Patelli G, Zampino MG, Bergamo F, Mosconi S, Tosi F, Ciardiello D, Lonardi S, Negrini G, Sibio D, Gerardi MA, Galuppo S, Filippone FR, Carnevali P, Borin S, Pilati P, Poiasina E, Bonazzina E, Gervaso L, Mammano E, Bracco F, Bergamaschi L, Spolverato G, Origi M, Romario UF, Mauri G, Fazio N, Forti E, De Roberto G, Cristofori C, Burti C, Asmundo L, Funicelli L, Ramondo G, Bonaffini PA, Mariano S, Lazzari L, Ghezzi S, Isella C, Cantarella D, Aquilano MC, Bottiglieri L, Bonoldi E, Mutignani M, Torri V, Medico E, Bardelli A, Marsoni S, Vanzulli A, Palazzi MF, Ferrari GC, Bencardino K, Sartore-Bianchi A, Siena S

Total neoadjuvant therapy followed by non-operative management or surgery in stage II-III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial.

Lancet Oncol 2025; 1612-1625. doi: 10.1016/S1470-2045(25)00542-X

Tiribelli C, Croce LS, Polo S, Sodde M, Stanta G

Incidence of hepatocellular carcinoma in Italy: what could we learn from autoptic studies?

Ital J Gastroenterol 1991; 448-51.

%PLACEHOLDER%